NC
IMVT icon

NinePointTwo Capital’s Immunovant IMVT Stock Holding History

NinePointTwo Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-55,942
Closed -$308K – 225
2022
Q1 		$308K Buy
55,942
+19,388
+53% +$121K 0.08% 110
2021
Q4 		$311K Buy
36,554
+26,386
+260% +$218K 0.1% 52
2021
Q3 		$88K Buy
+10,168
New +$91.7K 0.03% 75

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NinePointTwo Capital's IMVT Position: Q2 2022 in Review

NinePointTwo Capital sold out of Immunovant (IMVT) in Q2 2022, closing a stake of 55,942 shares — an estimated $308K sold.

NinePointTwo Capital first reported a position in IMVT in Q3 2021 and held it in 3 quarters. The position peaked at $311K in Q4 2021. 94 funds tracked by Wall St. Rank hold IMVT as of Q2 2022.

  • NinePointTwo Capital reported no remaining Immunovant position as of Q2 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 55,942 Immunovant shares in Q2 2022, an estimated $308K.
  • NinePointTwo Capital first reported a position in Immunovant in Q3 2021 and held it in 3 quarters.
  • NinePointTwo Capital's Immunovant position peaked at $311K in Q4 2021.
  • 94 funds tracked by Wall St. Rank held Immunovant as of Q2 2022.

Based on NinePointTwo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.